Three phase 3 randomised controlled trials have shown that patients with multiple myeloma receiving lenalidomide as maintenance therapy had significantly increased progression-free survival (PFS) and, in one study, improved overall survival.

The Lancet Oncology, Volume 13, Issue 6, Page e238, June 2012

Link to Document